• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: CHRISTOPH MIETHKE GMBH & CO KG PROGAV 2.0 WITH SHUNTASSISTANT 2.0 25; HYDROCEPHALUS MANAGEMENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

CHRISTOPH MIETHKE GMBH & CO KG PROGAV 2.0 WITH SHUNTASSISTANT 2.0 25; HYDROCEPHALUS MANAGEMENT Back to Search Results
Model Number FX649T
Medical Device Problem Codes Mechanical Problem (1384); Infusion or Flow Problem (2964)
Health Effect - Clinical Code Hydrocephalus (3272)
Date of Event 04/24/2022
Type of Reportable Event Serious Injury
Event or Problem Description
It was reported that a progav 2.0 shuntsytsem (part # fx643t) was implanted during a procedure performed in (b)(6) 2021.According to the complainant, the shunt system was believed to be operated in overdrainage and difficult to adjust.The patient underwent a revision procedure on (b)(6), 2022.The complaint device was returned to the manufacturer for evaluation.No patient complications were reported as a result of the revision procedure.Age: 2 years.Height: 100 centimeters (cm).Weight: 13 kilograms (kg).Gender: male.
 
Additional Manufacturer Narrative
Investigation: visual inspection: the following observations were made during the visual inspection: third-party catheter is closed by ligature.Permeability test: the test showed that both valves are permeable.Computer control test: the computer controlled test showed the opening pressure of the progav 2.0, at a reference flow rate of 20 ml/h in a horizontal position of the valve, to be 0,37 cmh2o.This is not within the specified tolerance of 5 cmh2o ± 3 cmh2o.An applied pressure of 5 cmh2o, with the device in the horizontal position is expected to have a resultant pressure of 5 cmh2o ± 3 cmh2o.According to our results, we can detect a presence of an accelerated outflow.Additionally, the shuntassistant 2.0 was tested according to standard procedure in the vertical position of the valve.At a fixed opening pressure of 25 cmh2o in the vertical position, a pressure of 25 cmh2o +4/-2 cmh2o is expected.The results indicated that at a reference flow of 20 ml/h in the vertical position, the shuntassistant 2.0 had a pressure of 23,54 cmh2o.This is within the specified tolerance of 25 cmh2o +4/-2 cmh2o.Adjustability test: the progav 2.0 was found to be not adjustable to specifications.The shuntassistant 2.0 is a fixed pressure valve, therefore the adjustability test is inapplicable.Braking force and brake function test: the braking force test indicates that the brake function of the progav 2.0 is present.Due to the non-adjustability of the valve, an investigation of the braking force was not possible.Internal inspection of product: in order to verify whether the investigated valves were compromised by the known risks of hydrocephalus therapy, e.G.By a build-up of natural substances (protein, blood, or tissue particles) in the cerebrospinal fluid, the valves are finally opened with a special tool.After dismantling of the valves, deposits were found in both valves.Results: for the sake of thoroughness and transparency, we would like to point out that an adjustment test and permeability test were already carried out after the revision at the hospital.Based on our investigation results, we have determined that there was an accelerated outflow and a non-adjustability in the progav 2.0 valve at the time of our investigation.Detected deposits were the cause of the functional deviation.Existing deposits in the csf can temporarily impair the function of the valve and is described as concomitant symptoms in hydrocephalus therapy.We can exclude a defect at the time of release.The valve / shunt system met all specifications of the final inspection when released from christoph miethke gmbh & co.Kg.From our point of view, no further regulatory actions are required.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
PROGAV 2.0 WITH SHUNTASSISTANT 2.0 25
Common Device Name
HYDROCEPHALUS MANAGEMENT
Manufacturer (Section D)
CHRISTOPH MIETHKE GMBH & CO KG
ulanenweg 2
potsdam, 14469
GM  14469
Manufacturer (Section G)
CHRISTOPH MIETHKE GMBH & CO KG
ulanenweg 2
potsdam, 14469
GM   14469
Manufacturer Contact
joerg knebel
ulanenweg 2
potsdam, 14469
GM   14469
MDR Report Key14519594
Report Number3004721439-2022-00143
Device Sequence Number14828181
Product Code JXG
UDI-Device Identifier04041906502072
UDI-Public4041906502072
Combination Product (Y/N)N
Initial Reporter CountryDA
PMA/510(K) Number
K190174
Number of Events Summarized1
Summary Report (Y/N)N
Device Explanted Year2022
Serviced by Third Party (Y/N)N
Reporter Type Manufacturer
Report Source Other,Foreign,User Facility,Company Representative
Initial Reporter Occupation Other Health Care Professional
Type of Report Initial
Report Date (Section B) 05/26/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Device Expiration Date05/13/2025
Device Model NumberFX649T
Device Catalogue NumberFX649T
Device Lot Number20047822
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer05/13/2022
Is the Reporter a Health Professional? Yes
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 04/29/2022
Initial Report FDA Received Date05/26/2022
Was Device Evaluated by Manufacturer? (Y/N) Yes
Date Device Manufactured05/14/2020
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Outcome Attributed to Adverse Event Required Intervention;
Patient Age2 YR
Patient SexMale
Patient Weight13 KG
-
-